贝达药业(300558) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥531,618,547.85, a decrease of 9.08% compared to ¥584,705,632.04 in the same period last year[5] - Net profit attributable to shareholders was ¥51,396,813.71, down 38.58% from ¥83,678,928.89 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥18,263,590.71, a significant decline of 75.50% from ¥74,547,457.21 in the previous year[5] - The company reported a net profit of CNY 35,503,476.58 for Q1 2023, down from CNY 95,809,100.26 in Q1 2022[20] - The total comprehensive income attributable to the parent company was ¥15.18 million, a decrease of 73.4% from ¥57.00 million in the previous year[21] - The company's other comprehensive income after tax was negative ¥36.21 million, compared to negative ¥26.67 million in the previous year[21] Cash Flow and Liquidity - The net cash flow from operating activities increased by 370.96% to ¥138,024,453.30, compared to ¥29,306,885.70 in the same period last year[7] - Cash and cash equivalents decreased to CNY 584,972,093.29 from CNY 731,284,859.68 at the beginning of the year, a decline of 20.1%[18] - Cash and cash equivalents at the end of the period were ¥584.97 million, down from ¥683.40 million at the end of Q1 2022[23] - The company incurred a net cash outflow from investing activities of approximately ¥534.31 million, compared to a net outflow of ¥567.12 million in the previous year[23] - The cash inflow from financing activities was approximately ¥1.14 billion, significantly higher than ¥438.02 million in Q1 2022[23] - The company paid approximately ¥709.57 million in cash related to financing activities, compared to ¥1.09 million in the previous year[23] Research and Development - R&D expenses rose by 62.91% to ¥175,355,803.09, reflecting increased investment in research projects[7] - In Q1 2023, the company invested CNY 245.87 million in R&D, a year-on-year increase of 52.74%[11] - R&D expenses surged to CNY 175,355,803.09, compared to CNY 107,640,306.79 in the previous year, indicating a focus on innovation[20] - The product Enasidenib was included in the National Basic Medical Insurance Drug List for first-line treatment indications[11] - The application for the registration of Bafetinib capsules for first-line treatment was accepted[11] - Clinical trial approvals were granted for multiple products, including BPB-101 and BPI-472372 tablets[11] Shareholder Information - The company has a total of 24,143 common shareholders at the end of the reporting period[8] - The largest shareholder, Ningbo Kaiming Investment Management Partnership, holds 19.18% of the shares[8] - The total number of restricted shares at the end of the period was 1,914,385 shares, with an increase of 289,800 shares during the period[10] - The company plans to release restricted shares for departing executives on May 22, 2023[10] - The company completed the cancellation of unexercised stock options from the 2018 incentive plan, totaling 44,586 shares[13] - The company reported a reduction in share pledges and a new pledge by shareholders in early 2023[16] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,979,049,580.53, a slight increase of 0.87% from ¥7,910,146,931.81 at the end of the previous year[5] - The company's total liabilities stood at CNY 2,980,876,476.83, slightly up from CNY 2,952,445,102.86[19] - The equity attributable to shareholders rose to CNY 4,893,721,514.96 from CNY 4,849,061,292.23, showing a modest increase[19] - Inventory levels increased to CNY 378,811,100.51 from CNY 372,172,656.68, indicating potential stockpiling or slower sales[18] - The company has a long-term investment of CNY 356,295,068.65, significantly up from CNY 107,767,074.61, suggesting strategic investments in growth[18] Operating Costs - Operating costs increased to CNY 531,203,279.54, up from CNY 498,844,724.48, reflecting a rise in operational expenses[20] - The total revenue from operating activities was ¥675.28 million, up 37.6% from ¥490.54 million in the previous year[22] Return on Equity - The weighted average return on equity decreased to 1.05%, down from 1.81% in the same period last year[5] - The company reported a basic and diluted earnings per share of ¥0.12, down from ¥0.20 in Q1 2022[21]